NCT00335868 2013-12-18PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL TherapyNational Cancer Institute (NCI)Phase 2 Unknown16 enrolled